SNPS

Prezzo Synopsys

Closed
SNPS
$410,00
+$13,79(+3,48%)

*Data last updated: 2026-04-08 00:42 (UTC+8)

As of 2026-04-08 00:42, Synopsys (SNPS) is priced at $410,00, with a total market cap of $76,22B, a P/E ratio of 54,56, and a dividend yield of 0,00%. Today, the stock price fluctuated between $388,88 and $411,87. The current price is 5,43% above the day's low and 0,45% below the day's high, with a trading volume of 896,80K. Over the past 52 weeks, SNPS has traded between $376,18 to $651,73, and the current price is -37,09% away from the 52-week high.

SNPS Key Stats

Yesterday's Close$397,07
Market Cap$76,22B
Volume896,80K
P/E Ratio54,56
Dividend Yield (TTM)0,00%
Diluted EPS (TTM)6,87
Net Income (FY)$1,33B
Revenue (FY)$7,05B
Earnings Date2026-05-27
EPS Estimate3,17
Revenue Estimate$2,24B
Shares Outstanding191,96M
Beta (1Y)1.148

About SNPS

Synopsys, Inc. provides electronic design automation software products used to design and test integrated circuits. The company offers Fusion Design Platform that provides digital design implementation solutions; Verification Continuum Platform that provides virtual prototyping, static and formal verification, simulation, emulation, field programmable gate array (FPGA)-based prototyping, and debug solutions; and FPGA design products that are programmed to perform specific functions. It also provides intellectual property (IP) solutions for USB, PCI Express, DDR, Ethernet, SATA, MIPI, HDMI, and Bluetooth low energy applications; analog IP, including data converters and audio codecs; and system-on-chip (SoC) infrastructure IP, datapath and building block IP, and verification IP products, as well as mathematical and floating-point components, and Arm AMBA interconnect fabric and peripherals. In addition, the company offers logic libraries and embedded memories; configurable processor cores and application-specific instruction-set processor tools for embedded applications; IP subsystems for audio, sensor, and data fusion functionality; and security IP solutions. Further, it provides Platform Architect solutions for SoC architecture analysis and optimization; virtual prototyping solutions; and HAPS FPGA-based prototyping systems, as well as a series of tools used in the design of optical systems and photonic devices. Additionally, the company offers security testing, managed services, programs and professional services, and training that enable its customers to detect and remediate security vulnerabilities, and defects in the software development lifecycle, as well as manufacturing solutions. It serves electronics, financial services, automotive, medicine, energy, and industrial areas. The company was incorporated in 1986 and is headquartered in Mountain View, California.
SectorTechnology
IndustrySoftware - Infrastructure
CEOSassine Ghazi
HeadquartersSunnyvale,CA,US
Official Websitehttps://www.synopsys.com
Employees (FY)28,00K
Average Revenue (1Y)$251,93K
Net Income per Employee$47,57K

Synopsys (SNPS) FAQ

What's the stock price of Synopsys (SNPS) today?

x
Synopsys (SNPS) is currently trading at $410,00, with a 24h change of +3,48%. The 52-week trading range is $376,18–$651,73.

What are the 52-week high and low prices for Synopsys (SNPS)?

x

What is the price-to-earnings (P/E) ratio of Synopsys (SNPS)? What does it indicate?

x

What is the market cap of Synopsys (SNPS)?

x

What is the most recent quarterly earnings per share (EPS) for Synopsys (SNPS)?

x

Should you buy or sell Synopsys (SNPS) now?

x

What factors can affect the stock price of Synopsys (SNPS)?

x

How to buy Synopsys (SNPS) stock?

x

Risk Warning

The stock market involves a high level of risk and price volatility. The value of your investment may increase or decrease, and you may not recover the full amount invested. Past performance is not a reliable indicator of future results. Before making any investment decisions, you should carefully assess your investment experience, financial situation, investment objectives, and risk tolerance, and conduct your own research. Where appropriate, consult an independent financial adviser.

Disclaimer

The content on this page is provided for informational purposes only and does not constitute investment advice, financial advice, or trading recommendations. Gate shall not be held liable for any loss or damage resulting from such financial decisions. Further, take note that Gate may not be able to provide full service in certain markets and jurisdictions, including but not limited to the United States of America, Canada, Iran, and Cuba. For more information on Restricted Locations, please refer to the User Agreement.

Other Trading Markets

Hot Posts su Synopsys (SNPS)

CoffeeNFTs

CoffeeNFTs

4 ore fa
Where can you find the best growth stocks to buy and watch? Start by checking the IBD 50, IBD Sector Leaders, IBD Big Cap 20, IPO Leaders and Stock Spotlight. You'll also find stocks like **Microsoft** (MSFT) and **Synopsys** (SNPS), whose track records of stable earnings growth have earned them a spot on IBD Long-Term Leaders. Be sure to check this page each day to see which stocks have just been added or removed from those screens. ↑ X This video file cannot be played.(Error Code: 102630) Inside Cathie Wood's 2025 Playbook: Disruption, Risk And A Massive Comeback For Speculative Growth Stocks See All Videos NOW PLAYING Inside Cathie Wood's 2025 Playbook: Disruption, Risk And A Massive Comeback For Speculative Growth Stocks IBD stock lists are based on The IBD Methodology, which helps identify today's most promising growth stocks by identifying those that are displaying the same traits that the best-performing stocks typically show in the early stages of a big move. But never buy a stock simply because it's on one of IBD's screens. Always do your own research and run all the stocks you're tracking through a buying checklist. And you can also use IBD's simple three-step routine to stay in sync with market conditions and make sure you have today's best growth stocks on your radar. IBD Newsletters --------------- #### Get exclusive IBD analysis and actionable news daily. SIGN UP NOW! IBD Newsletters --------------- #### Get exclusive IBD analysis and actionable news daily. * How To Invest * Market Prep * Tech Report Please enter a valid email address Please select a newsletter GO Get these newsletters delivered to your inbox & more info about our products & services. Privacy Policy & Terms of Use x Thank You! ---------- #### You will now receive IBD Newsletters ALL DONE! Something Went Wrong! --------------------- #### Please contact customer service CLOSE IBD Stock Lists Update ---------------------- ![](https://img-cdn.gateio.im/social/moments-76a34a3f81-72eb8a419d-8b7abd-badf29) AI Play Analog Devices Leads 14 Top Performers Onto These Best Stock ListsKeeping your watchlist up to date is key to making money in the stock market. IBD helps you do that by regularly updating stock screens like the IBD 50, IBD Big Cap... Read More ![](https://img-cdn.gateio.im/social/moments-9ad0db0919-bcc082d976-8b7abd-badf29) Gold Shines As 5 Hot Mining Firms Lead 13 Newcomers To Best Stock ListsIBD stock screens are regularly updated to add new stocks to watch, as well as weed out those that have started to show weakness. In the tables below, you'll see which stocks... Read More ![](https://img-cdn.gateio.im/social/moments-913b25f87f-395b08466b-8b7abd-badf29) Aris Mining Stock, Franco-Nevada, HSBC Among 30 New Stocks On IBD WatchlistsKeeping your watchlist up to date is key to making money in the stock market. IBD helps you do that by regularly updating stock screens like the IBD 50, IBD Sector Leaders,... Read More ![](https://img-cdn.gateio.im/social/moments-98477bca4a-a673f9e13d-8b7abd-badf29) Credicorp, Fabrinet, Comfort Systems, Jabil Among 30-Plus New Stocks On IBD WatchlistsKeeping your watchlist up to date is key to making money in the stock market. IBD helps you do that by regularly updating stock screens like the IBD 50, IBD Sector Leaders,... Read More ![](https://img-cdn.gateio.im/social/moments-d1948b30b3-bee41572e6-8b7abd-badf29) Alamos Gold Stock, Argan, Diversified Energy, 23 Others Join IBD Watchlists As Market LagsKeeping your watchlist up to date is key to making money in the stock market. IBD helps you do that by regularly updating stock screens like the IBD 50, IBD Sector Leaders,... Read More ###### View Past IBD Stock Lists Updates * * * Get Timely Buy And Sell Alerts With Leaderboard * * * **YOU MIGHT ALSO LIKE:** Join IBD Live And Learn Top Chart-Reading And Trading Techniques From The Pros Looking For The Next Breakout Stocks? Start Here Which Companies Are Now Outperforming 95% Of All Stocks? Want Weekly Tips On Investing? Get The 'How To Invest' Newsletter How To Buy Stocks | Buying Checklist When To Sell Stocks | Selling Checklist
1
0
0
0
SelfRugger

SelfRugger

04-06 13:52
This is a paid press release. Contact the press release distributor directly with any inquiries. New report: Medicare Advantage enrollment depicts industry at a crossroads, with concentrated growth and retrenchment ===================================================================================================================== PR Newswire Fri, February 27, 2026 at 2:00 AM GMT+9 3 min read _Enrollment slows as market resets under new economic realities. _ CHICAGO, Feb. 26, 2026 /PRNewswire/ -- HealthScape Advisors, a leading healthcare payer consulting firm, today announced the release of its annual 2026 Medicare Advantage competitive enrollment report. The report is a collaboration between Chartis and HealthScape Advisors, a Chartis Company. The Medicare Advantage market grew by 900,000 total beneficiaries to 35.4 million in PY2026, with enrollment rising 2.5% year over year, down from 3.6% in 2025 and 3.9% in 2024. This continued deceleration comes as many organizations intentionally scale back membership to prioritize margin for financial sustainability in a challenging regulatory and operating environment. Many are narrowing geographic footprints and reducing benefit richness. Expectations about market-wide enrollment are mixed for PY2027, but the long-term outlook remains positive. 77% of Medicare Advantage leaders expect the market will hold steady or continue to grow but at a lower rate than previous years. "We continue to see sustained moderation in growth year over year as Medicare Advantage experiences a period of recalibration and some for-profit organizations reevaluate their participation," said Alexis Levy, HealthScape Senior Partner and report co-author. "Despite slowed market growth, the majority of plan executives express optimism about the future of Medicare Advantage over the next five years." "Even as some plans retreat from certain markets and rethink benefit design, long-term confidence in the Medicare Advantage marketplace remains intact," said Nick Herro, Senior Partner in Strategic Transformation at Chartis and report co-author. "To remain competitive in this shrinking environment, plans are refining their growth strategy toward more predictable, targeted segments, like Special Needs Plans (SNPs)." The report explores key themes and takeaways changing the Medicare Advantage market, including: * **Enrollment trends:** Medicare Advantage enrollment rose 2.5% year over year, down from 3.6% in 2025, signaling a more constrained growth environment. Humana and a small subset of other challengers captured most net gains, benefiting from pullbacks by United and Aetna. * **SNP enrollment: **SNP enrollment jumped 12.2%, outpacing the broader market. Chronic Condition SNPs (C-SNP) continued to surge with 49% growth, as plans like Devoted, CareSource, and Molina gained traction. * **Plan options and preferences:** Total plan offerings fell 2.5% for the third straight year, driven by cuts to non-SNPs and a 10% drop in PPOs. Despite fewer plan offerings, enrollment patterns remained relatively stable. * **Quality ratings:** While average Star Ratings held steady, two-thirds of members (67.2%) are now enrolled in 4+ star plans, down sharply from roughly 80% earlier in the decade. Story Continues To view the full report, including the analytic methodology, click here. **About HealthScape Advisors** Every payer strives for better. At HealthScape Advisors, we help them achieve it. We partner with payers to deliver better member experiences, build better provider partnerships, and realize better health outcomes. We work with health plans and payers, ancillary and specialty health organizations, and healthcare investors and innovators to accelerate strategic growth; advance care quality, accessibility, and affordability; optimize operations; communicate with purpose and unlock the power of data. Our expertise across thousands of projects means we understand the landscape like no one else. When payers want meaningful results, they turn to HealthScape Advisors—the specialist who'll help them get to better. Learn more at www.healthscape.com. **About Chartis** The challenges facing US healthcare are longstanding and all too familiar. We are Chartis, and we believe in better. We work with more than 1,900 organizations annually to develop and activate transformative strategies, operating models, and organizational enterprises that make US healthcare more affordable, accessible, safe, and human. With more than 1,450 professionals, we help providers, payers, technology innovators, retail companies, and investors create and embrace solutions that tangibly and materially reshape healthcare for the better. Our family of brands—Chartis, Jarrard, Greeley, and HealthScape Advisors—is 100% focused on healthcare and each has a longstanding commitment to helping transform healthcare in big and small ways. Learn more. Chartis. Believe in better. Cision View original content: Terms and Privacy Policy Privacy Dashboard More Info
0
0
0
0